These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9395007

  • 1. Lodoxamide versus spaglumic acid: a comparative double-blind trial on patients suffering from seasonal allergic conjunctivitis induced by Parietaria pollen.
    Purello D'Ambrosio F, Gangemi S, Ricciardi L, Cuzzocrea S, Di Lorenzo G.
    Allergol Immunopathol (Madr); 1997; 25(5):233-7. PubMed ID: 9395007
    [Abstract] [Full Text] [Related]

  • 2. [Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases].
    Dekaris I, Gabrić N, Lazić R, Bosnar D, Cima I, Stipić A.
    Acta Med Croatica; 2002; 56(3):93-8. PubMed ID: 12630339
    [Abstract] [Full Text] [Related]

  • 3. A clinicopathological analysis of the efficacy of lodoxamide 0.1% eye drops on the conjunctiva of patients with vernal keratoconjunctivitis seen at Guinness Eye Centre, Lagos University Teaching Hospital.
    Adefule-Ositelu AO, Onakoya AO, Olasimbo OO, Adefule AK.
    Niger Postgrad Med J; 2006 Mar; 13(1):35-40. PubMed ID: 16633377
    [Abstract] [Full Text] [Related]

  • 4. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
    Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW.
    Clin Exp Allergy; 1997 Feb; 27(2):182-91. PubMed ID: 9061218
    [Abstract] [Full Text] [Related]

  • 5. Lodoxamide treatment of allergic conjunctivitis.
    Cerqueti PM, Ricca V, Tosca MA, Buscaglia S, Ciprandi G.
    Int Arch Allergy Immunol; 1994 Oct; 105(2):185-9. PubMed ID: 7920019
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of efficacy and safety of sterile solution of lodoxamide in patients with ocular allergy].
    Nicoară S.
    Oftalmologia; 2001 Oct; 52(2):81-4. PubMed ID: 11771108
    [Abstract] [Full Text] [Related]

  • 7. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
    Greiner JV, Udell IJ.
    Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
    [Abstract] [Full Text] [Related]

  • 8. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
    Richard C, Trinquand C, Bloch-Michel E.
    Eur J Ophthalmol; 1998 May; 8(4):207-16. PubMed ID: 9891891
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of single- and multiple-dose ketotifen fumarate 0.025% ophthalmic solution in a pediatric population.
    Abelson MB, Ferzola NJ, McWhirter CL, Crampton HJ.
    Pediatr Allergy Immunol; 2004 Dec; 15(6):551-7. PubMed ID: 15610370
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model.
    Abelson MB.
    Ann Allergy Asthma Immunol; 1998 Sep; 81(3):211-8. PubMed ID: 9759796
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G.
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [Abstract] [Full Text] [Related]

  • 12. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis.
    Blumenthal MN, Schwartz RH, Kaiser H.
    Ocul Immunol Inflamm; 2000 Sep; 8(3):159-67. PubMed ID: 11120577
    [Abstract] [Full Text] [Related]

  • 13. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
    Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR, Abelson MB, Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.
    Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
    [Abstract] [Full Text] [Related]

  • 14. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis.
    Shulman DG, Lothringer LL, Rubin JM, Briggs RB, Howes J, Novack GD, Hart K.
    Ophthalmology; 1999 Feb; 106(2):362-9. PubMed ID: 9951491
    [Abstract] [Full Text] [Related]

  • 15. [Value of the conjunctival provocation test in evaluating the activity of 2 concentrations of anti-allergy eyedrops, mequitazine].
    Dupin O, Compeyre S, Trinquand C, Persi L, Arnaud B.
    J Fr Ophtalmol; 1998 Jan; 21(1):12-8. PubMed ID: 9834894
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB, Greiner JV.
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model.
    Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC.
    Clin Ther; 2000 Jul; 22(7):826-33. PubMed ID: 10945509
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH, Harris J, LaVallee N, Russell H, Shilstone J.
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [Abstract] [Full Text] [Related]

  • 19. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis.
    Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E, Lodoxamide Study Group.
    Eur J Ophthalmol; 2001 Dec; 11(2):120-5. PubMed ID: 11456011
    [Abstract] [Full Text] [Related]

  • 20. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.
    Denis D, Bloch-Michel E, Verin P, Sebastiani A, Tazartes M, Helleboid L, Di Giovanni A, Lecorvec M.
    Br J Ophthalmol; 1998 Oct; 82(10):1135-8. PubMed ID: 9924299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.